

CS/BSE&NSE/2022-2023  
November 16, 2022

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Allotment of equity shares of the Company to the eligible equity shareholders on rights basis.**

**Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

This is further to our intimations dated June 24, 2022, October 12, 2022 and October 18, 2022 informing the approval of the Rights Issue by the board of directors (“Board”) and approval of the terms of the Rights Issue, record date and issue schedule by the Rights Issue Committee of the Board respectively.

In relation to the said Rights Issue and pursuant to the finalisation of the basis of allotment for the Rights Issue, approved by the designated stock exchange, i.e. BSE Limited on November 16, 2022, this is to inform that the Rights Issue Committee of the Board at its meeting held on November 16, 2022 (which commenced at 8.00 p.m. IST and concluded at 8.15 p.m. IST), has approved the allotment of 7,26,91,239 (Seven crore Twenty Six lakhs Ninety One thousand Two hundred and Thirty Nine) fully paid-up equity shares of the Company bearing distinctive numbers from 14,53,82,479 to 21,80,73,717 having a face value of Rs.1/- each in dematerialised form for cash at an issue price of Rs.55/- (Rupees Fifty Five Only) per equity share, i.e. at a premium of Rs.54/- (Rupees Fifty Four Only) per equity share, to the respective eligible equity shareholders (successful allottees) of the Company and / or renouncee(s) in terms of the letter of offer dated October 18, 2022.

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)



Post aforesaid allotment, the paid-up capital of the Company is Rs. 21,80,73,717/- (Rupees Twenty-One Crore Eighty Lacs Seventy-Three Thousand Seven Hundred and Seventeen Only) divided into 21,80,73,717 (Twenty-One Crore Eighty Lacs Seventy-Three Thousand Seven Hundred and Seventeen) fully paid-up equity shares having a face value of Rs.1/- (Rupees One only) each bearing ISIN INE495B01038.

This is for your information as also for the information of your members and the public at large.

Thanking You.

Yours faithfully,  
For **Suven Life Sciences Limited**

**Shrenik Soni**  
Company Secretary

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)